Clinical Trials Directory

Trials / Completed

CompletedNCT00681460

Metformin in Gestational Diabetes Mellitus

Effects of Insulin and/or Metformin Treatment on Perinatal Outcome and Metabolic Parameters in Women With Gestational Diabetes Mellitus: Prospective Randomized Trial.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
78 (actual)
Sponsor
K. Marcinkowski University of Medical Sciences · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

Gestational diabetes (GDM) is a condition that manifests as high blood sugar levels (hyperglycemia) during pregnancy in previously healthy women. It develops as a result of increased maternal body's resistance to insulin - a major hormone that allows for utilisation of glucose (sugar taken in with food) within cells. It was found out that GDM occurs more frequently in overweight women but also in women with a history of certain conditions such as polycystic ovary syndrome (PCOS). Usually, GDM disappears after pregnancy is completed but it is associated with some serious hazards for women and her unborn child, if untreated properly. Diet is a first-choice treatment but sometimes insulin therapy must be initiated if keeping a diet alone is not enough to maintain blood sugar within recommended values. Insulin therapy is effective but it requires several injections during each day and insulin is a strong acting hypoglycemic agent that may induce rapid falls in blood sugar, also dangerous for mother and unborn child. In the investigators study, the investigators would like to investigate if metformin that is a commonly used hypoglycemic drug can be effectively used for GDM treatment. Metformin has been used successfully for a long time to treat type 2 diabetes mellitus and PCOS and, according to current data, it is not dangerous neither for mother nor for baby when used during gestation.

Conditions

Interventions

TypeNameDescription
DRUGhuman recombined insulinmultiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
DRUGmetforminpills given orally twice up to three times a day, a total daily dosage 1000-2400 mg

Timeline

Start date
2008-05-01
Primary completion
2013-04-01
Completion
2013-05-01
First posted
2008-05-21
Last updated
2015-05-27

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT00681460. Inclusion in this directory is not an endorsement.